Matt Hewitt
Stock Analyst at Craig-Hallum
(3.49)
# 822
Out of 4,842 analysts
42
Total ratings
55.56%
Success rate
3.65%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $5.92 | +102.70% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $3.13 | +91.69% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $22.39 | +42.92% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $29.38 | +117.84% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $100.00 | +40.00% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $31.81 | +76.05% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $2.43 | +311.52% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $21.52 | +39.41% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.27 | +208.37% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $121.18 | +65.04% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.29 | +675.19% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $6.97 | +330.42% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.10 | +36,263.64% | 1 | Jan 4, 2022 |
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $5.92
Upside: +102.70%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $3.13
Upside: +91.69%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $22.39
Upside: +42.92%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $29.38
Upside: +117.84%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $100.00
Upside: +40.00%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $31.81
Upside: +76.05%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $2.43
Upside: +311.52%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $21.52
Upside: +39.41%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.27
Upside: +208.37%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $121.18
Upside: +65.04%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.29
Upside: +675.19%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $6.97
Upside: +330.42%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.10
Upside: +36,263.64%